APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly

Abstract

<h3>Background</h3><p>Neuroinflammation, characterized by increased reactivity of microglia and astrocytes in the brain, is known to be present at various stages of the Alzheimer’s disease (AD) <em>continuum</em>. However, its presence and relationship with amyloid pathology in cognitively normal at-risk individuals is less clear. Here, we used positron emission tomography (PET) and blood biomarker measurements to examine differences in neuroinflammation and beta-amyloid (Aβ) and their association in cognitively unimpaired homozygotes, heterozygotes, or non-carriers of the <em>APOE</em> ε4 allele, the strongest genetic risk for sporadic AD.</p><h3>Methods</h3><p>Sixty 60–75-year-old <em>APOE</em> ε4 homozygotes (<em>n</em> = 19), heterozygotes (<em>n</em> = 21), and non-carriers (<em>n</em> = 20) were recruited in collaboration with the local Auria biobank. The participants underwent ¹¹C-PK11195 PET (targeting 18-kDa translocator protein, TSPO), ¹¹C-PiB PET (targeting Aβ), brain MRI, and neuropsychological testing including a preclinical cognitive composite (APCC). ¹¹C-PK11195 distribution volume ratios and ¹¹C-PiB standardized uptake value ratios (SUVRs) were calculated for regions typical for early Aβ accumulation in AD. Blood samples were drawn for measuring plasma glial fibrillary acidic protein (GFAP) and plasma Aβ_1-42/1.40.</p><h3>Results</h3><p>In our cognitively unimpaired sample, cortical ¹¹C-PiB-binding increased according to <em>APOE</em> ε4 gene dose (median composite SUVR 1.47 (range 1.38–1.66) in non-carriers, 1.55 (1.43–2.02) in heterozygotes, and 2.13 (1.61–2.83) in homozygotes, <em>P</em> = 0.002). In contrast, cortical composite ¹¹C-PK11195-binding did not differ between the <em>APOE</em> ε4 gene doses (<em>P</em> = 0.27) or between Aβ-positive and Aβ-negative individuals (<em>P</em> = 0.81) and associated with higher Aβ burden only in <em>APOE</em> ε4 homozygotes (Rho = 0.47, <em>P</em> = 0.043). Plasma GFAP concentration correlated with cortical ¹¹C-PiB (Rho = 0.35, <em>P</em> = 0.040), but not ¹¹C-PK11195-binding (Rho = 0.13, <em>P</em> = 0.47) in Aβ-positive individuals. In the total cognitively unimpaired population, both higher composite ¹¹C-PK11195-binding and plasma GFAP were associated with lower hippocampal volume, whereas elevated ¹¹C-PiB-binding was associated with lower APCC scores.</p><h3>Conclusions</h3><p>Only Aβ burden measured by PET, but not markers of neuroinflammation, differed among cognitively unimpaired elderly with different <em>APOE</em> ε4 gene dose. However, <em>APOE</em> ε4 gene dose seemed to modulate the association between neuroinflammation and Aβ.</p>